ReviewLeukemia2026
Central nervous system involvement in acute lymphoblastic leukemia: pathogenesis and targeted therapy.
Review in Leukemia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Involvement of the central nervous system (CNS) is an adverse complication of acute lymphoblastic leukemia (ALL) associated with poor patient outcomes. Clinical challenges in the diagnosis and treatment of ALL in the CNS arise from an incomplete understanding of CNS disease pathogenesis, a significant barrier to developing novel therapeutics and biomarkers to address these challenges. A concerted research effort over recent years has significantly improved our understanding of CNS disease pathogenesis in ALL. Numerous CNS-infiltrating mechanisms by ALL cells have been uncovered, so recent research focuses on how ALL persists in this site. The role of the CNS microenvironment in the survival and therapy resistance of ALL is emerging, driven by ALL cell adhesion and metabolic reprogramming, revealing pathways with therapeutic potential. Here, we integrate recent advances in CNS infiltration and persistence in ALL, focusing on the signaling and metabolic frameworks that enable leukemic survival and therapy resistance once established in this site. We also evaluate novel therapeutic avenues and emerging targeted therapies that could enhance the efficacy of CNS-directed therapy in ALL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.